Teva Pharmaceutical Industries Limited (TEVA) - Stock Analysis
Last updated: Sep 20, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Teva raised its 2026 UZEDY outlook and received FDA approvals for DEGEVMA and WELTRUZA. Shares gained 5.7% over 21 trading days, though leverage and weak latest-quarter profitability limit conviction.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Earnings Deterioration ⢠Liquidity Pressure ⢠High Leverage TEVA's strong 2025 profitability and cash flow are being overshadowed by a weak latest quarter, deteriorating liquidity, high leverage, and elevated valuation risk.
Price Behavior
Key Price Behavior Insights: ⢠Constructive advance ⢠Key breakout ⢠Volatile pullbacks Support Level: $38.50â$38.70; stronger support $36.05â$36.35 Resistance Level: $39.25 TEVA gained 5.9% over the last month and remains bullish above its average, but traders should watch for a breakout above $39.25 or downside risk below $38.50.
Sentiment & News
Key News Insights: ⢠Credit upgrade ⢠Pipeline progress ⢠Debt refinancing Teva's growth strategy gains traction through pipeline progress, debt refinancing, credit upgrades, and portfolio expansion, though acquisition and pricing-policy risks remain.
AI Summary
Teva's investment case has shifted from distressed generics to a cash-generative branded-pharma turnaround, but upside requires Austedo, Ajovy, UZEDY and cost savings to outpace legacy erosion and convert $2.3â$2.5B annual operating cash flow into sustained deleveraging and margins. Investors should view it as an execution-driven hold/buy opportunity, closely monitoring branded growth and free cash flow given $17B of debt and fragile reported earnings.
Description
Teva Pharmaceutical Industries is a global pharmaceutical manufacturer and distributor of generic, specialty and biopharmaceutical products, supplying a broad range of dosage forms and active pharmaceutical ingredients to markets in North America, Europe and beyond. Its therapeutic portfolio spans central nervous system, respiratory, pain and oncology treatmentsâincluding established branded medicines such as Copaxone and AJOVYâand the company maintains collaborations for longâacting injectable formulations; Teva was founded in 1901 and is headquartered in Tel AvivâYafo, Israel.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 12 | Oct 19 | TEVA | Teva Pharmaceutical Industries Limited | Teva raised its 2026 UZEDY outlook and received FDA approvals for DEGEVMA and WELTRUZA. Shares gained 5.7% over 21 trading days, though leverage and weak latest-quarter profitability limit conviction. | Active | +0.0% |